Organ Transplant Immunosuppressant Drugs Market Outlook 2031
The global organ transplant immunosuppressant drugs market size was valued at USD 5.28 Billion in 2022 and likely reach to USD 7.07 Blliion by 2031, expanding at a CAGR of 3.3% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing need for transplantation, as well as technical advancements in organ transplantation and tissue engineering.
Organ transplantation is a medical operation that involves taking a missing or damaged organ from the donor and transplanting it into the recipient's body. Immunosuppressants are medications that suppress your immune system. The immune system of the body aids in the battle against pathogens that cause illness. However, the immune system can sometimes target healthy cells and tissues by mistake.
Immunosuppressive drugs can reduce or eliminate this reaction. Immunosuppressants may be prescribed to individuals who have Autoimmune disease, have had an organ transplant, or have had a stem cell or bone marrow transplant. In individuals with autoimmune diseases, the immune system misidentifies healthy tissue and cells as foreign invaders like germs. The immune system fights the body and turns against it.
This reaction can result in many types of autoimmune disorders depending on which area of the body is attacked. Immunosuppressive drugs suppress the immune system, preventing cell damage and inflammation. These medications help to reduce symptoms. They can even put an autoimmune condition into remission. Immunosuppressants help persons who have had organ transplants avoid organ rejection.
Your immune system recognizes that the new organ is not a natural component of your body. It sees the new organ as a danger and will attempt to eliminate it. Immunosuppressants regulate this reaction, ensuring that the new organ is protected. This new immune system sometimes perceives your body as alien. Healthy tissues and organs may be attacked by the immune system. Graft-versus-host disease (GVHD) develops as a result of this.
Immunosuppressive drugs reduce the risk of GVHD. Various intravenous (IV) or oral immunosuppressants are given to patients during and after a stem cell transplant for several weeks to months. Corticosteroids, such as prednisone, are among the most widely prescribed immunosuppressants by doctors. However, immunosuppressants come in a variety of types. For many patients, immunosuppressants could save their lives.
However, weakening your immune system might have negative consequences and increase your risk of health problems. The patient's condition will be closely monitored by the healthcare professional, who will also check for drug side effects. To attain the best effective treatment with the least number of side effects, a healthcare professional may adjust drugs or dose quantities.
Organ Transplant Immunosuppressant Drugs Market Trends, Drivers, Restraints, and Opportunities
- Increase in the number of patients who needs organ transplants is expected to boost the market growth during the forecast period.
- Growing incidence of kidney failure which in turn increases the demand for kidney transplant is anticipated to drive the market growth during the forecast period.
- Increasing number of product approvals and technological advancements are expected to boost the market growth in the coming years.
- Increasing shortage of organs for organ transplants is projected to hinder the market growth in the coming years.
- High cost of treatment is estimated to restrict the market growth during the forecast period.
- Increased R&D investment for tissue engineering, technological advancements in organ transplant are expected to offer lucrative opportunities for the market players.
Scope of Organ Transplant Immunosuppressant Drugs Market Report
The report on the global organ transplant immunosuppressant drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Antibodies), Transplant Type (Kidney, Liver, Heart, Lung, Pancreas, Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Astellas Pharma, Inc.; Sanofi Genzyme; Accord Healthcare Ltd.; Novartis AG, Mylan Laboratories, Inc.; Dr. Reddy’s Laboratories Ltd.; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Veloxis Pharmaceuticals A/S; and Bristol-Myers Squibb Company
|
Organ Transplant Immunosuppressant Drugs Market Segment Insights
Calcineurin inhibitors segment is expected to account for a key share of the market
Based on drug class, the organ transplant immunosuppressant drugs market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitor, steroids, antibodies. The calcineurin inhibitors segment is expected to account for a key share of the market during the forecast period owing to its effectiveness and long-term usage in kidney transplant recipients.
The market is projected to be driven further by an increase in the number of pipeline studies for organ transplant rejection. With the growing use of mTOR inhibitors and other innovative immunosuppressive drugs, solutions are emerging to reduce lifelong exposure to corticosteroids and calcineurin inhibitors while improving long-term outcomes.
Kidney segment is expected to constitute for a key share of the market
Based on transplant type, the organ transplant immunosuppressant drugs market is segmented into kidney, liver, heart, lung, pancreas, and others. The kidney segment is expected to constitute for a key share of the market during the forecast period due to rising demand and comparatively more organ availability than other transplants.
Furthermore, kidney transplants are discovered to be more cost-effective than dialysis over long periods of time. On the other hand, the liver and heart transplants segment are anticipated to expand at a rapid pace during the forecast period owing to its increased adoption rate.
Heart transplantation has changed end-stage heart failure treatments and is now considered the gold standard of care. Similarly, liver transplantation has become a life-saving operation for patients with chronic end-stage liver disease, acute liver failure (ALF), and alcoholic liver disease (ALD).
Calcineurin inhibitors segment is expected to account for a key share of the market
Based on distribution channel, the organ transplant immunosuppressant drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The Hospital pharmacies and retail pharmacies segment are expected to account for a key share of the market during the forecast period owing to its high penetration
On the other hand, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period due to increasing popularity of ecommerce channels. As online pharmacies offer a diverse range of alternatives and comprehensive information about these treatments, consumers are likely to prefer online channels during the forecast period.
Organ Transplant Immunosuppressant Drugs Market Regional Outlook
North America is anticipated to dominate the market
On the basis of regions, the organ transplant immunosuppressant drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to high healthcare investments, strong R&D infrastructure, attractive healthcare reimbursement schemes, and a large need for organ transplants.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increased investments in the healthcare industry by governments and companies, as well as a multitude of untapped potential. In this region, calcineurin inhibitors and mTOR inhibitors are generating more income for companies.
Segments
Drug Class
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitor
- Steroids
- Antibodies
Transplant Type
- Kidney
- Liver
- Heart
- Lung
- Pancreas
- Other
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Astellas Pharma, Inc.
- Sanofi Genzyme
- Accord Healthcare Ltd.
- Novartis AG
- Mylan Laboratories, Inc.
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Veloxis Pharmaceuticals A/S
- Bristol-Myers Squibb Company
Competitive Landscape
Key players competing in the organ transplant immunosuppressant drugs market include/are Astellas Pharma, Inc.; Sanofi Genzyme; Accord Healthcare Ltd.; Novartis AG, Mylan Laboratories, Inc.; Dr. Reddy’s Laboratories Ltd.; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Veloxis Pharmaceuticals A/S; and Bristol-Myers Squibb Company.
Many companies have lost patents of their products therefore the organ transplant immunosuppressant drugs market is facing tough competition from generic products. Some of the key business strategies adopted by companies are mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
